慢性淋巴细胞白血病并发自身免疫性溶血性贫血的研究进展

Progress of autoimmune hemolytic anemia with chronic lymphocytic leukemia

自身免疫性溶血性贫血（AIHA）是慢性淋巴细胞白血病（CLL）的一种较为常见的并发症，其发病机制复杂，CLL肿瘤细胞可通过直接分泌抗红细胞自身抗体或递呈红细胞自身抗原引发AIHA。根据患者的疾病特征，可选择糖皮质激素、免疫球蛋白、利妥昔单抗等多种治疗方案。AIHA患者通常对治疗应答良好，但容易复发，未来仍需进一步研究以优化治疗，提高患者的生存率。

Autoimmune hemolytic anemia （AIHA） is a common complication of chronic lymphocytic leukemia （CLL） with a complicated pathogenesis. CLL tumor cells can trigger AIHA by directly secreting autoantibodies targeting red blood cells or by presenting erythrocyte antigens. According to the disease features of different patients, multiple treatment regimens, such as glucocorticoid, immunoglohulin, rituximah and chemotherapy containing rituximab and glucocorticoid, could be chosen. AIHA patients respond well to the treatment, but it is easy to relapse. Further studies are needed to optimize the treatment and improve the overall survival of the patients.